Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,738
datasets available to search
ShareScore release 0.9.0
Dataset results
2,738 results for “multiple sclerosis”
Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis
<p><b>Objective: </b>To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort.</p> <p><b>Methods: </b>Using data from the MSBase Registry, we included pregnancies conceived after 31 Dec 2010 from women with relapsing-remitting MS or clinically isolated syndrome. Predictors of intrapartum relapse, and postpartum relapse and disability progression were determined by clustered logistic regression or Cox regression analyses.</p> <p><b>Results:</b> We included 1998 pregnancies from 1619 women with MS. Preconception annualized relapse rate (ARR) was 0.29 (95% CI 0.27-0.32), fell to 0.19 (0.14-0.24) in third trimester, and increased to 0.59 (0.51-0.67) in early postpartum. Among women who used fingolimod or natalizumab, ARR before pregnancy was 0.37 (0.28-0.49) and 0.29 (0.22-0.37), respectively, and increased during pregnancy. Intrapartum ARR decreased with preconception dimethyl fumarate use. ARR spiked after delivery across all DMT groups. Natalizumab continuation into pregnancy reduced the odds of relapse during pregnancy (OR 0.76 per month [0.60-0.95], p=0.017). DMT re-initiation with natalizumab protected against postpartum relapse (HR 0.11 [0.04-0.32], p<0.0001). Breastfeeding women were less likely to relapse (HR 0.61 [0.41-0.91], p=0.016). 5.6% of pregnancies were followed by confirmed disability progression, predicted by higher relapse activity in pregnancy and postpartum.</p> <p><b>Conclusion: </b>Women with MS prescribed natalizumab or fingolimod preconception had higher rates of intrapartum and postpartum relapse. In women considered to be at high relapse risk, use of natalizumab before pregnancy and continued up to 34 weeks gestation, with early re-initiation after delivery is an effective option to minimize relapse risks. Strategies of DMT use have to be balanced against potential fetal/neonatal complications.</p>
A systematic assessment of medical diagnoses preceding the first diagnosis of multiple sclerosis: Supplementary materials
<p class="Standard1"><b>Objective</b>: To explore the occurrence of diseases and symptoms in the five years prior to diagnosis in patients with multiple sclerosis (MS) in a case-control study.</p> <p class="Standard1"><b>Methods</b>: Using ambulatory claims data we systematically assessed differences in the occurrence of diseases and symptoms in the five years prior to first diagnosis in patients with MS (n=10,262) as compared to patients with two other autoimmune diseases – Crohn's disease (n=15,502) and psoriasis (n=98,432) - and individuals without these diseases (n=73,430).</p> <p class="Standard1"><b>Results</b>: Forty-three ICD-10 codes were recorded more frequently for patients with MS before diagnosis as compared to controls without autoimmune disease. Many of these findings were confirmed in a comparison to the other control groups. A high proportion of these ICD-10 codes represent symptoms suggestive of demyelinating events or other neurological diagnoses. In a sensitivity analysis excluding patients with such recordings prior to first diagnosis, no association remained significant. Seven ICD-10 codes were associated with lower odds ratios of MS, four of which represented upper respiratory tract infections. Here, the relations with MS were even more pronounced in the sensitivity analysis.</p> <p class="Standard1"><b>Conclusions</b>: Our analyses suggest that patients with MS are frequently not diagnosed at their first demyelinating event but often years later. Symptoms and physician encounters before MS diagnosis seem to be related to already ongoing disease rather than a prodrome. The observed association of upper respiratory tract infections with lower ORs of MS diagnosis suggests a link between protection from infection and MS that however needs to be validated and further investigated.</p>
Data from: Effects of age and disease duration on excess mortality in patients with multiple sclerosis from a French nationwide cohort
<p><strong>Objective: </strong>To determine the effects of current age and disease duration on excess mortality in multiple sclerosis, we described the dynamics of excess deaths rates over these two time scales and studied the impact of age at multiple sclerosis clinical onset on these dynamics, separately in each initial phenotype.</p> <p><strong>Methods: </strong>We used data from 18 French multiple sclerosis expert centers participating in the Observatoire Français de la Sclérose en Plaques. Patients with multiple sclerosis living in metropolitan France and having a clinical onset between 1960 and 2014 were included. Vital status was updated on January 1st, 2016. For each multiple sclerosis phenotype separately (relapsing onset (R-MS) or primary progressive (PPMS)), we used an innovative statistical method to model the logarithm of excess death rates by a multidimensional penalized spline of age and disease duration.</p> <p><strong>Results: </strong>Among 37524 patients (71% women, mean age at multiple sclerosis onset ± standard deviation 33.0 ± 10.6 years), 2883 (7.7%) deaths were observed and 7.8% of patients were lost-to-follow-up. For R-MS patients, there was no excess mortality during the first 10 years after disease onset; afterwards, whatever age at onset, excess death rates increased with current age. From current age 70, the excess death rates values converged and became identical whatever the age at disease onset, which means that disease duration had no more impact. Excess death rates were higher in men with an excess hazard ratio of 1.46 (95% confidence interval 1.25-1.70). In contrast, in PPMS patients, excess death rates rapidly increased from disease onset, and were associated with age at onset, but not with sex.</p> <p><strong>Conclusions:</strong> In R-MS, current age has a stronger impact on multiple sclerosis mortality than disease duration while their respective effects are not so clear in PPMS. </p>
Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches
<p>Background and Purpose: The limbic brain is involved in diverse cognitive, emotional, and autonomic functions. Injury of the various parts of the limbic system have been correlated with clinical deficits in MS. The purpose of this study was to comprehensively examine different regions of the subcortical limbic system to assess the extent of damage within this entire system as it may be pertinent in correlating with specific aspects of cognitive and behavioral dysfunction in MS by using a fully automated, unbiased segmentation approach. </p> <p>Results: The mean [95% confidence interval] of the total limbic system volume was lower (0.22% [0.21-0.23]) in MS compared to healthy controls (0.27%, [0.25-0.29], p < .001). Pairwise comparisons of individual limbic regions between MS and controls was significant in the nucleus accumbens (0.046%, [0.043-0.050] vs. 0.059%, [0.051-0.066], p = .005), hypothalamus (0.062%, [0.059-0.065] vs. 0.074%, [0.068-0.081], p = .001), basal forebrain (0.038%, [0.036-0.040] vs. 0.047%, [0.042-0.051], p = .001), hippocampus (0.47%, [0.45-0.49] vs. 0.53%, [0.49-0.57], p = .004), and anterior thalamus (0.077%, [0.072-0.082] vs. 0.093%, [0.084-0.10], p = .001) after Bonferroni correction. Volume of several limbic regions was significantly correlated with T2 lesion burden and brain parenchymal fraction (BPF). Multiple regression model showed minimal influence of BPF on limbic brain volume and no influence of other demographic and disease state variables. VBM analysis showed cluster differences in the fornix and anterior thalamic nuclei at threshold p < 0.05 after adjusting for covariates but the results were insignificant after family-wise error corrections. </p> <p>Conclusions: The results show evidence that brain volume loss is fairly extensive in the limbic brain. Given the significance of the limbic system in many disease states including MS, such volumetric analyses can be expanded to studying cognitive and emotional disturbances in larger clinical trials. FreeSurfer ScLimbic pipeline provided an efficient and reliable methodology for examining many of the subcortical structures related to the limbic brain. </p>
Dataset for "Investigating the Relationship Between Cognitive Functions and Clinical and Individual Characteristics in Iranian Multiple Sclerosis Patients"
<p>Instruction and tests are in persian Laguage. </p>
Data from: Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis
Objective: To develop and implement an evidence based framework to select, from drugs already licenced, candidate oral neuroprotective drugs to be tested in secondary progressive multiple sclerosis. Design: Systematic review of clinical studies of oral putative neuroprotective therapies in MS and four other neurodegenerative diseases with shared pathological features, followed by systematic review and meta-analyses of the in vivo experimental data for those interventions. We presented summary data to an international multi-disciplinary committee, which assessed each drug in turn using pre-specified criteria including consideration of mechanism of action. Results: We identified a short list of fifty-two candidate interventions. After review of all clinical and pre-clinical evidence we identified ibudilast, riluzole, amiloride, pirfenidone, fluoxetine, oxcarbazepine, and the polyunsaturated fatty-acid class (Linoleic Acid, Lipoic acid; Omega-3 fatty acid, Max EPA oil) as lead candidates for clinical evaluation. Conclusions: We demonstrate a standardised and systematic approach to candidate identification for drug rescue and repurposing trials that can be applied widely to neurodegenerative disorders.
Fig. 1 in Triterpene glycosides from Blighia welwitschii and evaluation of their antibody recognition capacity in multiple sclerosis
Fig. 1. Structures of new triterpene saponins 1–7 isolated from the fruits of B. welwitschii.
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis
ClinicalTrials.gov study NCT00393588. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
ClinicalTrials.gov study NCT02727907. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
ClinicalTrials.gov study NCT03396822. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00662649. IPD Sharing: Not stated. Countries: 22. Publications: 0.
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov study NCT01874340. IPD Sharing: Not stated. Countries: 10. Publications: 0.
The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial
ClinicalTrials.gov study NCT01034579. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
ClinicalTrials.gov study NCT01517282. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
ClinicalTrials.gov study NCT00654927. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
ClinicalTrials.gov study NCT01044576. IPD Sharing: NO. Countries: 1. Publications: 0.
Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis
ClinicalTrials.gov study NCT06012513. IPD Sharing: Not stated. Countries: 0. Publications: 2.
Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
ClinicalTrials.gov study NCT01236534. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
ClinicalTrials.gov study NCT01317004. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: Project EXACT
ClinicalTrials.gov study NCT03677440. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.